| Heading: |
Multiple Sclerosis: Medical Treatments |
| Question ID: |
1812404 |
| UIN: |
59658 |
| House: |
Commons |
| Date tabled: |
2025-06-12 |
| Asking Member ID: |
5239 |
| Asking Member display name: |
Sarah Gibson
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sarah Gibson
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of high-efficacy treatments for relapsing-remitting MS on the NHS. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-18 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NHS in England is leg... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |